Words by Josh Hardman with support from Psychedelic Alpha Medical Advisor Michael Haichin. *** Today, Transcend Therapeutics shared topline results from its Phase 2 study of the MDMA analog methylone (TSND-201) in PTSD. The trial, IMPACT-1 (NCT05741710), enrolled 65 severe PTSD patients to receive either methylone or placebo capsules once weekly for four weeks…
